Analyst rates Pfizer Inc. a Buy as oncology, Eliquis and tafamidis may offset its three-year patent cycle; 2026 EPS guidance rises to $2.95-$3.05.
Pfizer (PFE) pays China-based Starna Therapeutics $330M upfront to receive ex-China rights to CAR-T drugs in a deal worth up to $2.6B. Read more here.
At 9.6 times guidance-midpoint earnings with a 5.95% dividend yield, Pfizer stock looks inexpensive.
Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.
Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.
Pfizer partners with Blackstone, securing up to $1.5bn in funding for berobenatide, a potential first-in-class monthly GLP-1 agonist for obesity.
More players enter growing market as domestic spending per animal rises
Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer’s berobenatide through 2028 in exchange for milestone-based payments.
The investment is set to cover development costs for berobenatide, an investigational drug being studied for chronic weight management and obesity-related conditions.
Medicus Pharma Ltd (MDCX) outlined its CD228V license from Pfizer, a proposed $135 million SkinJet SPAC combination and a $35.9 million nine-month net loss amid tight liquidity.
This is the newest page. Registered accounts read further back.